Clinical Trial Update: ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1/2 study of ALXN2350 in adults with BAG3 mutation-associated dilated cardiomyopathy, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy

Drugs mentioned

• ALXN2350

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: BAG3 Mutation Associated Dilated Cardiomyopathy | Phase 1, Phase 2 | Status: RECRUITING